Clinical Trial Update: Efficacy and Safety Study of SYR-619 in Treating Subjects With Type 2 Diabetes Mellitus [Phase 2]

View source ↗

Summary

SYR-619, evaluated for Type 2 diabetes mellitus in a Phase 2 trial sponsored by Takeda, has been terminated. No efficacy or safety results are provided in this …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• SYR-619

Snippet

Sponsor: Takeda | Conditions: Diabetes Mellitus | Phase 2 | Status: TERMINATED